Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Cancer Research

• Publication date

  2007-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-07-0970PMID 17652141
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations.

  2006cited by this paper
• Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice.

  2006cited by this paper
• Pancreatic cancer in mice and man: the Penn Workshop 2004.

  2006cited by this paper
• Pancreatic cancer: a review of recent advances

  2006cited by this paper
• Chemoprevention of spontaneous development of hepatocellular carcinomas in fatty liver Shionogi mice by a cyclooxygenase‐2 inhibitor

  2006cited by this paper
• Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor.

  2005cited by this paper
• Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice.

  2005cited by this paper
• Precursors to Invasive Pancreatic Cancer

  2005cited by this paper
• Regression of Mouse Prostatic Intraepithelial Neoplasia by Nonsteroidal Anti-inflammatory Drugs in the Transgenic Adenocarcinoma Mouse Prostate Model

  2004cited by this paper
• Combined effects of cyclooxygenase‐1 and cyclooxygenase‐2 selective inhibitors on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice

  2004cited by this paper
• Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model.

  2004cited by this paper
• The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice.

  2003cited by this paper
• Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

  2003cited by this paper
• Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse.

  2003influential reference
• Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer.

  2002cited by this paper
• Mouse by Rofecoxib , a Specific Cyclooxygenase-2 Inhibitor 716 ∆ Apc Chemoprevention of Intestinal Polyposis in the Updated Version

  2001cited by this paper
• Molecular genetics of ductal pancreatic neoplasia

  2000cited by this paper
• Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice.

  1998cited by this paper
• GASTROENTEROLOGY 2006;130:2165–2178 Preinvasive Duct-Derived Neoplasms in Pancreas of Keratin 5–Promoter Cyclooxygenase-2 Transgenic Mice

  year unknowncited by this paper

• Copper-KRAS-COX2 Axis: A Therapeutic Vulnerability in Pancreatic Cancer.

  2025cites this paper
• Early elevations of RAS protein level and activity are critical for the development of PDAC in the context of inflammation.

  2024cites this paper
• Ductal metaplasia in pancreas.

  2022cites this paper
• Molecular signaling in pancreatic ductal metaplasia: emerging biomarkers for detection and intervention of early pancreatic cancer

  2022cites this paper
• Obesity and Pancreatic Cancer: Insight into Mechanisms

  2021cites this paper
• Islet Inflammation: The Link between Type 2 Diabetes and Pancreatic Cancer

  2021cites this paper
• The Unique Microbiome and Immunity in Pancreatic Cancer

  2021cites this paper
• Tumor cell-intrinsic EPHA2 suppresses anti-tumor immunity by regulating PTGS2 (COX-2).

  2019cites this paper
• Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development

  2019cites this paper
• The association between use of statin or aspirin and pancreatic ductal adenocarcinoma: A nested case‐control study in a Korean nationwide cohort

  2019cites this paper
• Lipophilic statins inhibit YAP nuclear localization, co-activator activity and colony formation in pancreatic cancer cells and prevent the initial stages of pancreatic ductal adenocarcinoma in KrasG12D mice

  2019cites this paper
• Nimesulide inhibits proliferation and induces apoptosis of pancreatic cancer cells by enhancing expression of PTEN.

  2018cites this paper
• Myeloid-derived macrophages and secreted HSP90α induce pancreatic ductal adenocarcinoma development

  2018cites this paper
• The Interface of Pancreatic Cancer With Diabetes, Obesity, and Inflammation: Research Gaps and Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

  2018cites this paper
• Metformin Decreases the Incidence of Pancreatic Ductal Adenocarcinoma Promoted by Diet-induced Obesity in the Conditional KrasG12D Mouse Model

  2018cites this paper
• Tepoxalin a dual 5-LOX-COX inhibitor and erlotinib an EGFR inhibitor halts progression of gastric cancer in tumor xenograft mice.

  2018cites this paper
• PRDM14 is overexpressed in chronic pancreatitis prior to pancreatic cancer

  2018cites this paper
• Deficiency in hormone-sensitive lipase accelerates the development of pancreatic cancer in conditional KrasG12D mice

  2018cites this paper
• Deficiencies in Natural Killer Cell Numbers, Expansion, and Function at the Pre-Neoplastic Stage of Pancreatic Cancer by KRAS Mutation in the Pancreas of Obese Mice

  2018cites this paper
• Expression of neuropeptide Y and its receptors Y1 and Y2 in pancreatic intraepithelial neoplasia and invasive pancreatic cancer in a transgenic mouse model and human samples of pancreatic cancer.

  2018cites this paper
• KRAS, YAP, and obesity in pancreatic cancer: A signaling network with multiple loops.

  2017cites this paper
• Direct growth‐inhibitory effects of prostaglandin E2 in pancreatic cancer cells in vitro through an EP4/PKA‐mediated mechanism

  2017cites this paper
• Oncogenic KRAS and the Inflammatory Micro-Environment in Pancreatic Cancer

  2017cites this paper
• The role of inflammatory modulators in chronic pancreatitis and the development of pancreatic cancer

  2017cites this paper
• Suppression of Gingival NK Cells in Precancerous and Cancerous Stages of Pancreatic Cancer in KC and BLT-Humanized Mice

  2017cites this paper
• Incidence of pancreatic cancer is dramatically increased by a high fat, high calorie diet in KrasG12D mice

  2017cites this paper
• Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer

  2017cites this paper
• The Mouse Model of Pancreatic Cancer Atlas (MMPCA) for classification of pancreatic cancer lesions: A large histological investigation of the Ptf1aCre/+;LSL-KrasG12D/+ transgenic mouse model of pancreatic cancer

  2017cites this paper
• K-Ras and cyclooxygenase-2 coactivation augments intraductal papillary mucinous neoplasm and Notch1 mimicking human pancreas lesions

  2016cites this paper
• Animal models of pancreatic cancer and their application in clinical research

  2016cites this paper
• Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.

  2016cites this paper
• Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancer.

  2016cites this paper
• Robust Early Inflammation of the Peripancreatic Visceral Adipose Tissue During Diet-Induced Obesity in the KrasG12D Model of Pancreatic Cancer

  2016cites this paper
• Mutant KRAS Enhances Tumor Cell Fitness by Upregulating Stress Granules.

  2016cites this paper
• Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma

  2015cites this paper
• Prostaglandin E2 activates the mTORC1 pathway through an EP 4 /cAMP/ PKA- and EP 1 /Ca 2 -mediated mechanism in the human pancreatic carcinoma

  2015cites this paper
• Somatostatin Receptor Subtype 2 as Pancreatic Tumorigenesis Suppressor: Identification of a New Targetable Signaling Node

  2015cites this paper
• Somatostatin receptor subtype 2 as pancreatic tumorigenesis suppressor: identification of a new targetable signaling node.

  2015cites this paper
• Molecular Targeted Intervention for Pancreatic Cancer

  2015cites this paper
• Pancreatic Stellate Cells

  2015cites this paper
• Targeting pancreatitis blocks tumor-initiating stem cells and pancreatic cancer progression

  2015cites this paper
• Prostaglandin E2 activates the mTORC1 pathway through an EP4/cAMP/PKA- and EP1/Ca2+-mediated mechanism in the human pancreatic carcinoma cell line PANC-1.

  2015cites this paper
• Urinary Prostaglandin E2 Metabolite and Pancreatic Cancer Risk: Case-Control Study in Urban Shanghai

  2015cites this paper
• E-cadherin expression in obesity-associated, Kras-initiated pancreatic ductal adenocarcinoma in mice.

  2015cites this paper
• Impact of diabetes type II and chronic inflammation on pancreatic cancer

  2015cites this paper
• Chronic Pancreatitis as an Inductor of Pancreatic Cancer — Correlations With Inflammatory Pathways

  2015cites this paper
• Chronic pancreatitis: a path to pancreatic cancer.

  2014cites this paper
• Pathogenesis of Pancreatic Cancer

  2014cites this paper
• The role of inflammation in pancreatic cancer.

  2014cites this paper
• Interleukin-6: a villain in the drama of pancreatic cancer development and progression.

  2014cites this paper
• Biology of Human Tumors Inhibition of Tumor-Derived Prostaglandin-E 2 Blocks the Induction ofMyeloid-DerivedSuppressorCells andRecovers Natural Killer Cell Activity

  2014cites this paper
• A historical perspective of pancreatic cancer mouse models.

  2014cites this paper
• Involvement of eicosanoids in the pathogenesis of pancreatic cancer: the roles of cyclooxygenase-2 and 5-lipoxygenase.

  2014cites this paper
• Pancreatic cancer and its stroma: a conspiracy theory.

  2014cites this paper
• Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity

  2014cites this paper
• Stars and stripes in pancreatic cancer: role of stellate cells and stroma in cancer progression

  2014cites this paper
• Impact of non-steroidal anti-inflammatory drugs on gastrointestinal cancers: current state-of-the science.

  2014cites this paper
• Downstream of Mutant KRAS, the Transcription Regulator YAP Is Essential for Neoplastic Progression to Pancreatic Ductal Adenocarcinoma

  2014cites this paper
• Requirement of NEMO/IKKγ for effective expansion of KRAS-induced precancerous lesions in the pancreas

  2013cites this paper
• A method for conducting highly sensitive microRNA in situ hybridization and immunohistochemical analysis in pancreatic cancer.

  2013cites this paper
• Exploiting inflammation for therapeutic gain in pancreatic cancer

  2013cites this paper
• Macrophage-secreted cytokines drive pancreatic acinar-to-ductal metaplasia through NF-κB and MMPs

  2013cites this paper
• Prostaglandin E2 Regulates Pancreatic Stellate Cell Activity Via the EP4 Receptor

  2013cites this paper
• Evaluating dietary compounds in pancreatic cancer modeling systems.

  2013cites this paper
• A Novel Combinatorial Nanotechnology-Based Oral Chemopreventive Regimen Demonstrates Significant Suppression of Pancreatic Cancer Neoplastic Lesions

  2013influential citation
• The spectrum of achalasia: lessons from studies of pathophysiology and high-resolution manometry.

  2013cites this paper
• High-Fat, High-Calorie Diet Promotes Early Pancreatic Neoplasia in the Conditional KrasG12D Mouse Model

  2013cites this paper
• Efficacy of Dimethylaminoparthenolide and Sulindac in Combination With Gemcitabine in a Genetically Engineered Mouse Model of Pancreatic Cancer

  2013cites this paper
• The Biology of K-Ras Signaling Pathways in Pancreatic Cancer

  2013cites this paper
• PGE2 Regulates Pancreatic Stellate Cell Activity Via The EP4 Receptor

  2013cites this paper
• Prolonged survival and delayed progression of pancreatic intraepithelial neoplasia in LSL-KrasG12D/+;Pdx-1-Cre mice by vitamin E δ-tocotrienol.

  2013cites this paper
• Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer

  2013cites this paper
• Challenges and advances in mouse modeling for human pancreatic tumorigenesis and metastasis

  2012cites this paper
• Involvement of inflammatory factors in pancreatic carcinogenesis and preventive effects of anti-inflammatory agents

  2012cites this paper
• Celecoxib Enhances the Anti-inflammatory Effects of Farnesylthiosalicylic Acid on T Cells Independent of Prostaglandin E2 Production

  2012cites this paper
• Chemoprevention of pancreatic cancer—one step closer

  2012cites this paper
• The HMGA1-COX-2 axis: a key molecular pathway and potential target in pancreatic adenocarcinoma.

  2012cites this paper
• Early detection and prevention of pancreatic cancer: use of genetically engineered mouse models and advanced imaging technologies.

  2012cites this paper
• CURRENT AND FUTURE STRATEGIES FOR THERAPY OF PANCREATIC CANCER

  2012cites this paper
• An NF-κB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice.

  2012cites this paper
• Inhibition of pancreatic intraepithelial neoplasia progression to carcinoma by nitric oxide-releasing aspirin in p48(Cre/+)-LSL-Kras(G12D/+) mice.

  2012cites this paper
• Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/+ LSL‐KrasG12D/+ mice

  2012cites this paper
• An investigation of the prognostic value of pathological and genomic factors in pancreatic ductal adenocarcinoma

  2012cites this paper
• Cell Intrinsic Role of COX-2 in Pancreatic Cancer Development

  2012cites this paper
• What we have learned about pancreatic cancer from mouse models.

  2012cites this paper
• Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer

  2011cites this paper
• Precursor Lesions of Pancreatic Cancer

  2011cites this paper
• ROLE OF PROSTAGLANDIN E2 IN THE REGULATION OF PANCREATIC STELLATE CELLS HYPER ACTIVITY ASSOCIATED WITH PANCREATIC CANCER

  2011cites this paper
• The Utility of Transgenic Mouse Models for Cancer Prevention Research

  2011cites this paper
• Cyclooxygenase-2 Confers Growth Advantage to Syngeneic Pancreatic Cancer Cells

  2011cites this paper
• Involvement of COX-2/PGE2 Pathway in the Upregulation of MMP-9 Expression in Pancreatic Cancer

  2011cites this paper
• Experimental Animal Models of Pancreatic Carcinogenesis for Prevention Studies and Their Relevance to Human Disease

  2011cites this paper
• RAGE Gene Deletion Inhibits the Development and Progression of Ductal Neoplasia and Prolongs Survival in a Murine Model of Pancreatic Cancer

  2011cites this paper
• CXCR2-Dependent Endothelial Progenitor Cell Mobilization in Pancreatic Cancer Growth.

  2011cites this paper
• Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressing translational oncology

  2011cites this paper
• Recent developments of transgenic and xenograft mouse models of pancreatic cancer for translational research

  2011cites this paper
• COX-2 expression in adenoma: an imperfect marker for chemoprevention

  2010cites this paper
• Similar antineoplastic effects of nimesulide, a selective COX-2 inhibitor, and prostaglandin E1 on B16-F10 murine melanoma cells

  2010cites this paper
• Modelling a dream: the molecular prevention of pancreatic cancer

  2010cites this paper
• The molecular pathology of precursor lesions of pancreatic cancer

  2010cites this paper